Breast Cancer Steering Committee

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The NCI Breast Cancer Steering Committee (BCSC) was established in September 2008.

Mission Statement

The BCSC functions to coordinate an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in breast cancer clinical research by addressing the design and prioritization of phase 3 and large phase 2 trials in breast cancer.

Roster of Breast Cancer Steering Committee (BCSC) members


2015 Breast Cancer Steering Committee Strategic Priorities

Task Forces

BOLD (Breast Oncology Local Disease): Mark Basik, M.D. and Rich Zellars, M.D., Co-chairs

BOLD Resources:

North American Breast Cancer Group (NABCG) Correlative Sciences Committee

BCSC Activities

Clinical Trial Planning Meetings (CTPM)

Workshops and Meetings

2009 Brain Metastases Workshop

2008 Pharmacogenetics Research Network/Breast Cancer Intergroup/NCI Summit

2007 Preoperative Breast Cancer Meeting

Clinical Trials

The following are clinical trials that were approved at the concept stage by the Steering Committee.

Trial IDNCT IDTrial Title
NCIC CTG-MA.32 NCT01101438 A Phase III Randomized Trial of the Effect of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
SWOG-S1007 NCT01272037 A Phase III, Randomized Clinical Trial of Standard Adjuvant EndocrineTherapy +/- Chemotherapy in Patients with 1-9 Positive Nodes, Hormone-responsive and HER2-negative Breast Cancer according to Recurrence Score (RS)
ECOG-E2108 NCT01242800 A Randomized Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer
RTOG-1005 NCT01349322 A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus Concurrent Boost Versus Standard Whole Breast Irradiation with Conventional Fractionation plus Sequential Boost for Early-Stage Breast Cancer
NSABP B-49 NCT01547741 A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
RTOG-1119 NCT01622868 Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients with Brain Metastasis From HER2-Positive Breast Cancer – A Collaborative Study of RTOG and KROG
NSABP B-51/RTOG-1304 NCT01872975 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
SWOG-1207 NCT01674140 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
NSABP B-52 NCT02003209 A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or Without Estrogen Deprivation
ALLIANCE-A011202 NCT01901094 A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
ECOG-ACRIN E2112 NCT02115282 A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

Find all NCI-sponsored clinical trials.

CCCT Contact: Jennifer Hayes, Ph.D.